OrphoMed to Present at the 2018 BIO CEO & Investor Conference

January 31, 2018

SAN FRANCISCO, CA– OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that Nikhilesh N. Singh, Ph.D., President and Chief Executive Officer, will present at the 20th Annual BIO CEO & Investor Conference, being held February 12-13, 2018, in New York City.

PRESENTATION DATE: February 12, 2018

TIME: 9:30 a.m. EST

LOCATION: New York Marriott Marquis, Gilbert Room, 4th Floor

A copy of the presentation will be available at www.orphomed.com.

About OrphoMed, Inc.

OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics for patients with gastrointestinal disorders. Leveraging its proprietary dimer platform technology, OrphoMed is advancing ORP-101, a potential best-in-class buprenorphine dimer in clinical development for the treatment of IBS-D, and its pipeline of additional dimer conjugates. For more information please visit www.orphomed.com.

CONTACT:
Gregory L. Beyer
Vice President, Finance & Operations
(415) 569-4417
glb@orphomed.com